Neurocords Overview
Neurocords is developing regenerative therapies for spinal cord injuries. Its focus is on a novel cellular therapy platform aimed at restoring function following spinal cord injuries.
Latest News
growth-positive
Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
Orgenesis Inc., a global biotech company, announced the acquisition of Neurocords LLCs assets related to regenerative medicine therapies for spinal cord injuries. This strategic acquisition aims to expand access to cost-effective treatments by integrating Neurocords technology with Orgenesiss decentralized cell processing approach. The acquisition involves an equity transaction, with Orgenesis issuing 1,200,000 shares of common stock to Neurocords. Orgenesis plans to leverage its AI-based technology to enhance the production of autologous stem cells, potentially accelerating the development of transformative therapies for spinal cord injuries. The acquisition aligns with Orgenesiss mission to improve healthcare outcomes through innovative cell and gene therapies.
AcquisitionPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 0 |
| Investors | 0 |
Team Members
0
Employees: 0
Web & Social Links
Locations
HaRakevet St 58, Tel Aviv-Yafo, Israel
Photos & Videos
No files yet
Neurocords Business
Business models
B2B
Product stage
Released
Employees
0
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTarget Customer
—Core Technology
—Neurocords Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Acquired
Funding stage
0
Total rounds
0
Investors
Public Offering / Exit
MNAEvent
Mar 2025
Undisclosed
Neurocords Lifecycle
All Events
MNAEvent
Mar 2025
Undisclosed
Neurocords News
1 article
growth-positive
Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
Orgenesis Inc., a global biotech company, announced the acquisition of Neurocords LLCs assets related to regenerative medicine therapies for spinal cord injuries. This strategic acquisition aims to expand access to cost-effective treatments by integrating Neurocords technology with Orgenesiss decentralized cell processing approach. The acquisition involves an equity transaction, with Orgenesis issuing 1,200,000 shares of common stock to Neurocords. Orgenesis plans to leverage its AI-based technology to enhance the production of autologous stem cells, potentially accelerating the development of transformative therapies for spinal cord injuries. The acquisition aligns with Orgenesiss mission to improve healthcare outcomes through innovative cell and gene therapies.
AcquisitionPartners
Neurocords Team
No team members listed.
Employee Info
| Employees (range) | 0 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 2 classification IDs that could be used for matching.
Neurocords Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 46/100 |
| Missing | sector, tags, invite member, logo, description, homepage, video or image, funding rounds, markets, external profiles, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515813897 |
| Creator | Maor Perlov |
| Creator email | maor.perlov@sncentral.org |
| Last update | 2025-03-25T00:00:00.000Z |
| Created | 2025-03-25T00:00:00.000Z |
| Status detail | Acquired by Orgenesis on Mar, 2025 |